Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Beaufour-Ipsen moves TH-9506 to phase I

Nov. 27, 1997

First marketing approval granted for Neumega

Nov. 26, 1997

PTK inhibitors for bone disorders from Novartis

Nov. 26, 1997

Roussel Uclaf discloses integrin antagonists for bone disorders

Nov. 26, 1997

ProLease hGH slated to enter phase III

Nov. 26, 1997

Sertoli and Carolinas Medical Center collaborate to develop novel diabetes therapy

Nov. 26, 1997

FDA approves sibutramine for the treatment of obesity

Nov. 25, 1997

Bayer introduces statin in Germany

Nov. 25, 1997

Novel beta-agonists for obesity and diabetes described by SmithKline Beecham

Nov. 25, 1997

Dainippon's aldose reductase inhibitor in preclinical testing

Nov. 25, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...